Meeting
2013 ASCO Annual Meeting
Novel toxicity endpoint for dose-finding designs evaluating molecularly targeted agents (MTA).
Authors
Monia Ezzalfani
Institut Gustave Roussy, Biostatistics and Epidemiology Department, Villejuif, France
Monia Ezzalfani , Sarah Zohar , Sumithra J. Mandrekar , Gilles Vassal , Marie-Cécile Le Deley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cytotoxic and Other Novel Agents
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2577)
DOI
10.1200/jco.2013.31.15_suppl.2577
Abstract #
2577
Poster Bd #
6E
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase I trial of an alpha-lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC).
First Author: George Thomas Budd
Poster
2021 ASCO Annual Meeting
A risk stratification model for toxicities in phase 1 immuno-oncology (P1-IO) trials.
First Author: Alberto Hernando-Calvo
Poster
2018 ASCO Annual Meeting
Systematic review of pediatric oncology phase I trials: Toxicity and outcomes in the era of targeted therapies.
First Author: Julia Wanda Cohen
Poster
2017 Gastrointestinal Cancers Symposium
Phase I study of gemcitabine (G), dasatinib (D), and erlotinib (E) in advanced pancreatic carcinoma (PC).
First Author: Dana Backlund Cardin